Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
A Japanese health ministry panel on March 2 recommended approvals for Daiichi Sankyo’s measles-mumps-rubella (MMR) vaccine, Haihe Biopharma’s PI3Kα inhibitor risovalisib, and MSD’s once-daily HIV combination doravirine/islatravir. The Pharmaceutical Affairs Council’s Second Committee on Drugs endorsed three new molecular entities…
To read the full story
Related Article
- Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
- Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
- Xocova Filed for Post-Exposure Prophylaxis for COVID-19 in Japan
March 28, 2025
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
- MHLW Clarifies Up to 12-Year Data Protection for Pediatric Development
March 2, 2026
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…